US67080T1088 - Common Stock
NUVECTIS PHARMA INC
NASDAQ:NVCT (11/12/2024, 8:21:54 PM)
After market: 10.44 -0.54 (-4.92%)10.98
+0.17 (+1.57%)
Nuvectis Pharma, Inc. is a preclinical stage biopharmaceutical company. The company is headquartered in Fort Lee, New Jersey and currently employs 13 full-time employees. The company went IPO on 2022-02-04. The firm is developing two drug candidates: NXP800 and NXP900. NXP800 is an oral small molecule GCN2 activator, which is in a Phase 1b clinical trial for the treatment for platinum resistant, ARID1a-mutated ovarian carcinoma and in an investigator-sponsored clinical trial for the treatment of cholangiocarcinoma. NXP800 activates the GCN2 kinase inducing inhibition of cap-dependent protein translation and activation of the integrated stress response leading to cancer cell death. NXP900 is a targeted-therapy, small molecule drug candidate that inhibits the proto-oncogene c-Src (SRC) and YES1 kinases, which is undergoing a Phase 1a dose escalation study. SRC is aberrantly activated in many cancer types, including solid tumor cancers such as breast, colon, prostate, pancreatic and ovarian cancers.
NUVECTIS PHARMA INC
1 Bridge Plaza, Suite 275
Fort Lee NEW JERSEY
P: 13608377232
Employees: 13
Website: https://nuvectis.com/
The US market is yet to commence its session on Tuesday, but let's get a preview of the pre-market session and explore the top gainers and losers driving the early market movements.
Clinical data update from the NXP800 Phase 1b study expected this month; NXP800 granted Orphan Drug Designation for the treatment of ARID1a-deficient...
Here you can normally see the latest stock twits on NVCT, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.
Example Twits: